55044-76-3

Upstream product

• 623-73-4 diazoacetic acid ethyl ester 
• 456-39-3 3-chlorobenzenediazonium tetrafluoroborate 
• 35229-83-5 ethyl 2-chloro-2-(2-(3-chlorophenyl)hydrazono)acetate 
• 1443759-17-8 N'-(3-chlorophenyl)-2-ethoxyacetohydrazonamide 
• 108-42-9 3-chloro-aniline 

Downstream Products

• 1368985-29-8 2-(3-chloro-phenyl)-2H-tetrazole-5-carboxylic acid 
• 956360-16-0 1-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-ethanone 

Relevant academic research and scientific papers

Regioselective synthesis of carboxylic and fluoromethyl tetrazoles enabled by silver-catalyzed cycloaddition of diazoacetates and aryl diazonium salts

Here we present a dipolar [3 + 2] cycloaddition transformation of diazoacetates with arenediazonium salts under silver catalysis, thus offering a straightforward approach for the regioselective construction of carboxylic tetrazoles. Several merits are accompanied with this reaction including readily available starting reagents, broad coupling scope, high yields, and friendly reaction conditions. The synthetic value is further showcased by one-pot conversion of commercially available primary arylamines to tetrazoles and successful transformations of the cycloadducts into valuable 5-fluoromethyltetrazoles and an analogue of P2X3 receptor antagonist.

PIPERAZINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLU5 RECEPTORS

This invention relates to compounds of formula (I) their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. R1, R2, R3, R4, Q have meanings given in the description.

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. R1, R2, R3, R4, Q have meanings given in the description.